• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 16.48
  • VXN 19.83
  • VXO 17.26
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





YES
Refresh      
AMRN (Amarin Corporation plc)
Last Trade 17.51 Dividend/Share 0 PE Ratio -44.9
Date March 22-2019 Dividend Yield 0.000 Return on Assets -42.55
Change -1.25 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -0.39 Price/Sale 26.953
Ask null LatestEPS Date 2018-12-31 Price to Book 44.19
Volume null EPS ttm -0.390 Institutional % 57.5
Avg Volume 8.04M Shares Outstanding 329.32M Insider % 0.9
Open 18.8 Float 326.6M Short Ratio null
Prev Close 18.76 Return On Equity -567.8 5 Year Change % 8.949
High 19.367 Consensus EPS -0.08 2 Year Change % 4.489
Low 17.48 No. of Estimate 2.000 1 Year Change % 4.541
52 Week High 23.335 EPS Surprise $ null YTD Change % 0.346
52 Week Low 2.35 EPS Surprise Percent -37.5 6 Month Change % 0.412
52 Week Change 461.218 EBITDA 0M 3 Month Change % 0.411
50 Day MA 18.5174 Revenue 0M 1 Month Change % -0.106
200 Day MA Gross Profit 0M 5 Day Change % -0.093
Market Cap 5766.42M Cash 0M 30 Day Change % 0.042
Beta 1.30122 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
12
Company Profile

Amarin Corporation plc operates as a biopharmaceutical company with a focus on cardiovascular diseases. Its cardiovascular programs focus in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. The company?s lead product candidate includes AMR101, a prescription grade Omega-3 product comprising ultra-pure ethyl eicosapentaenoic acid, which is entering Phase III clinical trials for the treatment of hypertriglyceridemia and mixed dyslipidemia. Its pipeline also includes programs in the area of central nervous system disorders, including Huntington?s disease, myasthenia gravis, and Parkinson?s disease. Amarin Corporation plc, formerly known as Ethical Holdings plc, was founded in 1989 and is based in Dublin, Ireland.